MSF frequently publishes updates, press releases, and other forms of communication about its work in roughly 70 countries around the world. See the list below for the most recent updates or search by location, topic, or year.

Country/Region

 

Although tuberculosis (TB) is preventable and curable, it is the second-biggest infectious disease killer behind HIV and claims nearly 1.3 million lives each year.

The spread of drug-resistant strains of the disease is increasingly recognized as a public health emergency. Drug-resistant tuberculosis (DR-TB) is an umbrella term that refers to tuberculosis strains which resist the drugs routinely used to treat conventional TB.

More >

In the mountainous region of Nagaland, northeast India, Doctors Without Borders/Médecins Sans Frontières (MSF) is working with local groups and health authorities to treat people with drug-resistant tuberculosis (DR-TB), a form of the disease that does not respond to the two main drugs used to treat TB. The two-year regimen for treating DR-TB is extremely arduous and can cause patients to become blind or deaf and can cause organ failure. MSF is calling for better diagnosis and treatment for DR-TB. Support the Test Me, Treat Me DR-TB Manifesto. Sign now at http://msfaccess.org/TBmanifesto/.

More >

Outgoing International President MSF Dr. Unni Karunakara is taking to the road on a bicycle to travel 5000 kilometers in India to spark dialogue on health, health care, and humanitarianism.

More >

A House subcommittee held a hearing on international trade disputes with India. Most of the event was devoted to U.S. drug company Pfizer's complaints about Indian policies that have fostered the country's billion-dollar generics industry.

More >

MSF testifies in Congress on India's right to keep lifesaving medicines affordable.

More >

On April 1, 2013, a landmark ruling by India's Supreme Court ensured continued access to affordable HIV medication for the millions affected by this disease, including the 220,000 patients that Doctors Without Borders/Médecins Sans Frontières (MSF) treats with generic HIV/AIDS medication. This access has been under threat for the past seven years by pharmaceutical company Novartis, which challenged a section of India's Patents Act that prevented the practice of "evergreening," or extending the patent of an existing medicine by modifying it slightly. By extending patents, pharmaceutical companies prevent the manufacture of generic drugs. The ruling by India's Supreme Court is a victory for those fighting for access to affordable medicine—at least, for the time being.

More >

  A landmark ruling by India's Supreme Court underscores the need for patients to have access to generic medications at affordable prices, according to MSF's Jennifer Cohn.

More >

MSF launched the Patent Opposition Database as part of the campaign to boost access to medicines in countries where patients can't afford the high drug prices some companies seek to preserve.  

More >

In this blog post from BMJ Group Blogs, lawyer and India manager of MSF's Access Campaign Leena Menghaney discusses the two legal battles that are taking center stage in the struggle over India's medicines patent law.

More >

Novartis AG goes to India's Supreme Court on Wednesday to seek patent protection for its blockbuster cancer drug Glivec in a case that could deliver far-reaching ramifications for multinational pharmaceutical companies operating in India.... Novartis's critics, including Médecins Sans Frontières [Doctors Without Borders], say that if the company prevails, it could set a legal precedent that allows pharmaceutical giants to patent a range of drugs in India that are now available from generic producers, including HIV medicines. That would demolish a thriving low-cost industry and lead to higher prices, not just in India, they say, but elsewhere in the developing world where India is a major exporter of drugs.

More >

Pages